Product Using Direct Data Entry Receives FDA Marketing Clearance
According to Target Health, this is the first product to be approved using for in its pivotal trial, direct data entry of patient data at the time of the clinic visit into an EDC system, with no need for paper records.
The FDA has cleared for marketing a medical cooling device from Lund, Sweden-based Dignitana. Digitana engaged Target Health as its CRO, using its web-based eSource-enable EDC system to collect direct data entry from patients. According to Target Health, this is the first product to be approved using in its pivotal trial, direct data entry of patient data at the time of the clinic visit into an EDC system, with no need for paper records.
Target Health and three major medical centers were inspected with no FDA findings related to Target Health’s approach to the paperless clinical trial. Digitana originally submitted for approval in March 2015.
Target Health is also reporting that an NDA with seven studies using the same paperless approach was submitted November 25 to the FDA, with other international submissions planned. Additionally, two pivotal trials in neurology are underway, as well as a study integrating EDC with the electronic medical record, which will begin in Q2 2016.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
